Join Neuropathix, Inc. CEO Dean Petkanas at the 7th CB1, CB2, & Cannabinoid Drug Development Summit next week, November 18-20, 2024 in Boston, MA hosted by Hanson Wade Group. https://lnkd.in/enmcc5-J Kannalife Sciences, Inc. Kannalife, Inc. #Research #Cannabinoids #PeripheralNeuropathy #NeuroPain #Innovation #HealthScience #Neuroscience #MedicalResearch #Inflammation #GPCR #GPR55 #CIPN #Mitochondria
Kannalife, Inc.
制药业
Doylestown，Pennsylvania 220 位关注者
a subsidiary of Neuropathix, Inc. (OTCQB:NPTX)
关于我们
Kannalife, Inc. is a biopharmaceutical company leading innovation in research, development, and discovery of natural and novel biomimetic cannabinoid therapeutic agents. The Company is focused on the development of proprietary cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports. The Company's family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
- 网站
-
https://www.neuropathix.com
Kannalife, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- Doylestown，Pennsylvania
- 类型
- 上市公司
- 创立
- 2013
地点
-
主要
获取路线
3805 Old Easton Rd
US，Pennsylvania，Doylestown，18902
动态
-
Join our CEO Dean Petkanas at the 7th CB1, CB2, & Cannabinoid Drug Development Summit November 18-20, 2024 | Boston, MA hosted by Hanson Wade Group. https://lnkd.in/enmcc5-J
Dean Petkanas - 7th CB1, CB2 & Cannabinoid Drug Development Summit
cannabinoid-derived-drug-development.com
-
Article from Parkinson's News Today earlier this month on our Kannalife Sciences, Inc. $1.49M grant award from The Michael J. Fox Foundation for Parkinson's Research This grant will support the development of our lead therapeutic, #KLS13019, addressing neuroinflammation and mitochondrial dysfunction—two key factors in Parkinson’s disease. #ParkinsonsResearch #Biotech #Research #Innovation #neuroiflammation #mitochondria #mitochondrialdysfunction #GPCR #GPR55 #NCX1 #mNCX1 #NLRP3 #CannabinoidTherapeutics #Neurodegeneration #Neuropathix Neuropathix, Inc. #Kannalife #MJFF https://lnkd.in/gpXfX5xy
MJFF $1.49M grant to advance preclinical research into KLS-13019
https://parkinsonsnewstoday.com
-
We are thrilled to share that Kannalife Sciences, Inc. has secured $1.49 million in funding from The Michael J. Fox Foundation for Parkinson's Research. This grant will support the development of our lead therapeutic, KLS-13019, addressing neuroinflammation and mitochondrial dysfunction—a key factor in Parkinson’s disease. Our heartfelt thanks to The Michael J. Fox Foundation, our dedicated team, and research partners. Together, we are advancing the frontier of neurodegenerative disease treatment. #ParkinsonsResearch #Biotech #Research #Innovation #CannabinoidTherapeutics #Neurodegeneration #Kannalife #MJFF
We are thrilled to share that Kannalife Sciences, Inc. has secured $1.49 million in funding from The Michael J. Fox Foundation for Parkinson's Research. This grant will support the development of our lead therapeutic, KLS-13019, addressing neuroinflammation and mitochondrial dysfunction—a key factor in Parkinson’s disease. Our heartfelt thanks to The Michael J. Fox Foundation, our dedicated team, and research partners. Together, we are advancing the frontier of neurodegenerative disease treatment. #ParkinsonsResearch #Biotech #Research #Innovation #CannabinoidTherapeutics #Neurodegeneration #Kannalife #MJFF https://lnkd.in/gC4qmGdK
Kannalife Secures Funding of $1.49 Million from The Michael J. Fox Foundation for Parkinson’s Research
globenewswire.com
-
Save the Date: Our CEO Dean Petkanas is presenting at the BIO International Convention on Tuesday, June 4, 2024 at 4:30pm in Company Presentation Theater 3. Join us also at the NIH booth #825 Tuesday, June 4, 2024 at 11:56 am
We're excited and honored to announce that Kannalife Sciences, Inc. has been selected by the The National Institutes of Health (NIH) as one of the 30 NIH SEED Companies to have earned the privilege to present at the BIO International Convention in San Diego. Save the Date: Our CEO Dean Petkanas is presenting on Tuesday, June 4, 2024 at 4:30pm in Company Presentation Theater 3. Join us also at the NIH booth #825 Tuesday, June 4, 2024 at 11:56 am for a closer look. Thank you to the NIH for the recognition of our team’s commitment and tireless efforts in researching treatments for diseases with unmet medical needs. #bio #bio2024 #NIH #NINDS #pharma #biotech #biotechnology #kannalife #neuropathix #research https://lnkd.in/eVvqkZnh
Dean Petkanas
convention.bio.org
-
At last week's BioNJ BioPartnering Conference, CEO Dean Petkanas of Neuropathix, Inc. and Kannalife Sciences, Inc. featured in ROI-NJ, where he highlighted New Jersey's prominent role in the pharmaceutical biotech sector. It's clear that NJ remains a top choice for life science startups and the state continues to draw interest due to its strong infrastructure and support. #BioNJ #LifeSciences #Biotech #Pharma #Innovation #Networking
At last week's BioNJ BioPartnering Conference, CEO Dean Petkanas of Neuropathix, Inc. featured in ROI-NJ, where he highlighted New Jersey's prominent role in the pharmaceutical biotech sector. It's clear that NJ remains a top choice for life science startups and the state continues to draw interest due to its strong infrastructure and support. #BioNJ #LifeSciences #Biotech #Pharma #Innovation #Networking https://lnkd.in/ewihdEfv
At BioPartnering event, it’s easy to find cheerleaders for (and critics of) state | ROI-NJ
https://www.roi-nj.com
-
?? New Research Alert! Kannalife Sciences, Inc. Scientists uncover a link between KLS-13019 and the GPR55 receptor, shedding light on its promising role in reducing inflammatory markers associated with chemotherapy-induced peripheral neuropathy (CIPN). In contrast, cannabidiol (CBD) shows low efficacy, highlighting significant differences between the two compounds. Our recent study in the Journal of Molecular Neuroscience investigates the anti-inflammatory actions of KLS-13019 and CBD in CIPN. ?? Insights from this study pave the way for targeted therapies and innovative approaches to treating inflammation. Stay tuned. ?? Read the full study here: https://rdcu.be/dFqru Neuropathix, Inc. #Research #Cannabinoids #PeripheralNeuropathy #NeuroPain #Innovation #HealthScience #Neuroscience #MedicalResearch #Inflammation #GPCR #GPR55 #CIPN #Mitochondria
Knockdown siRNA Targeting GPR55 Reveals Significant Differences Between the Anti-inflammatory Actions of KLS-13019 and Cannabidiol - Journal of Molecular Neuroscience
link.springer.com
-
Dean Petkanas CEO of Neuropathix, Inc. and Kannalife Sciences, Inc. presenting “KLS-13019 - A Remarkable Non-Opioid Drug Discovery for the Treatment of Neuro Pain” on Tune in on April 2, 2024 @ 11:30am EST / 8:30am PST https://lnkd.in/guAsZkYi
1) Recruitment: BioTech & Medical Device 2) Training: Diversity & Inclusion - darshanavnadkarni.wordpress.com
All invited to join tomorrow April 2 at 8:30 am PST talk on zoom - "KLS-13019 - A Remarkable Non-Opioid Drug Discovery for the Treatment of Neuro Pain" by Dean Petkanas, CEO at Kannalife, Inc. - see link in comments. With Harry Wachob RONALD SCHOENGOLD, RAC, FRAPS Patrick Lee Stan Levy